MAIN ARTICLE
A promising result that fell short of approval
Summit reported receiving a complete response letter, the FDA’s formal notification that the biologics application cannot be approved in its current form. That is not a declaration that the molecule has no activity, nor does it halt all research. It means the regulator considered the evidence insufficient for the specific population and treatment combination under review.
The proposed indication concerned people with locally advanced or metastatic non-small cell lung cancer after treatment with an EGFR-targeted tyrosine kinase inhibitor. Such drugs can control tumors driven by EGFR abnormalities, but resistance commonly emerges. More options are urgently needed, although a new regimen must demonstrate a persuasive balance between clinical benefit and unwanted effects.
Published HARMONi findings showed median progression-free survival of 6.8 months with ivonescimab plus chemotherapy, compared with 4.4 months on chemotherapy alone. A hazard ratio of 0.52 indicates a 48% relative reduction in the risk of progression or death during observation. It does not mean 48% more patients were cured, or that the treatment prolonged life by that percentage.
















